ArticleJournal of advanced research2026
TMEM158 promotes ICC metastasis via inducing lactic acid mediated reduction of actin skeleton stiffness of ICC cells.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Histone variant H2A.J is an epigenetic regulator of metastasis in lung adenocarcinoma.Cell death & disease · 2026Article
- Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma.Journal of molecular medicine (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe survival rate of patients with intrahepatic cholangiocarcinoma (ICC) is extremely low mainly because of its high metastatic characteristic, pushing us to explore effective targets inhibiting the metastasis of ICC.
objectivesTo explore potential therapeutical targets to restrict the metastasis of ICC.
methodsThe potential targets were screened via RNA sequencing and verified in cells and tissues. The prognostic value of TMEM158 was explored in ICC patients. The abilities of TMEM158 on affecting the metastasis of ICC were detected in cells and mice models. The cell actin skeleton stiffness was measured by phalloidin staining. The effect of TMEM158 on lactic acid (LA) generation was explored via metabolic flow and relative mechanism was detected by co-immunoprecipitation and immunofluorescence. The relationship between HIF-1A and TMEM158 was explored by dual luciferase reporter gene experiment.
resultsTMEM158 was identified as a potential candidate over-expressed in ICC, especially with metastasis, that is linked to reduced overall survival. Besides, functional studies indicated that TMEM158 silencing inhibits ICC metastasis in vivo and in vitro through decreasing cell actin skeleton stiffness of ICC cells, and visa versa. Moreover, mechanically, lactic acid (LA) is validated as the bridge connecting TMEM158 and skeleton stiffness and TMEM158 induces the generation of LA via interaction with and activating Ras protein and subsequently enhancing glucose transporter 3 (Glut3) mediated glycolysis in ICC cells. Finally, HIF-1A directly targets the promoter region of TMEM158 and thus increases its level in ICC.
conclusionTMEM158 reduced the actin skeleton stiffness of ICC cells through activating Ras protein mediated generation of LA, which finally results in enhanced metastasis of ICC. Our work provides a preclinical evidence of concept for TMEM158 as a novel candidate inhibiting the metastasis of ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.